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A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus
(HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate
(TDF), atazanavir, indinavir and lopinavir) or apparent changes in renal function (e.g. cobicistat, ritonavir, rilpivirine
and dolutegravir). Patients with HIV are at higher risk of acute and chronic renal dysfunction, so baseline assessment
and ongoing monitoring of renal function is an important part of routine management of patients with HIV.
Given the paucity of evidence in this area, we sought to establish a consensus view on how routine monitoring
could be performed in Australian patients on ART regimens, especially those involving TDF. A group of
nephrologists and prescribers (an HIV physician and a hepatologist) were assembled by Gilead to discuss practical
and reasonable renal management strategies for patients particularly those on TDF-based combination regimens
(in the case of those with HIV-infection) or on TDF-monotherapy (in the case of HBV-mono infection). The group
considered which investigations should be performed as part of routine practice, their frequency, and when
specialist renal referral is warranted. The algorithm presented suggests testing for serum creatinine along with
plasma phosphate and an assessment of urinary protein (rather than albumin) and glucose.
Here we advocate baseline tests of renal function at initiation of therapy. If creatinine excretion inhibitors (e.g.
cobicistat or rilpivirine) are used as part of the ART regimen, we suggest creatinine is rechecked at 4 weeks and this
value used as the new baseline. Repeat testing is suggested at 3-monthly intervals for a year and then at least yearly
thereafter if no abnormalities are detected. In patients with abnormal baseline results, renal function assessment
should be performed at least 6 monthly. In HBV mono-infected patients advocate that a similar testing protocol
may be logical.
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Introduction
Human immunodeficiency virus (HIV) infection has now
become a chronic disease for most patients treated with
antiretroviral therapy (ART) [1]. The improvement in
prognosis has however unmasked a vulnerability to life-
style and metabolic diseases like diabetes and hyperten-
sion, and has highlighted the potential for rare side effects* Correspondence: steve.holt@mh.org.au
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unless otherwise stated.of ART, including the nephrotoxic potential of some drugs
[2]. HIV-infected individuals have higher risks of both
acute and chronic kidney disease (CKD) [3-6] than the
general population. Thus the monitoring of renal function
and identification and treatment of risk factors for CKD
are important elements of HIV management. For most
patient groups, this can be done in line with existing
guidelines, such as the Kidney Health Check [7]. However
in the monitoring of patients on some antiretroviral
agents there are key differences to this routine review. A
recent Australian study found that there is room to im-
prove the management of renal disease in HIV-infected
patients [8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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disoproxil fumarate (TDF) has become the most widely
used antiretroviral agent in HIV-infected patients and is
listed as a preferred ART regimen in major guidelines
[9-11]. Although preclinical studies and early clinical
data did not identify any renal safety issues for TDF, a
series of case reports and large population studies have
suggested it has nephrotoxic potential in some HIV-
infected patients, albeit with a low frequency [12-15].
Monitoring patients in order to pick up nephrotoxicity and
proactive dose adjustment form part of routine HIV care.
However, national and international guidelines lack detailed
guidance for clinicians in the timing and nature of such
monitoring (European AIDS Clinical Society [16] (EACS),
British HIV Association [17] (BHIVA), US DHHS United
States department of Health and Human Services [18]).
An expert panel convened by Gilead in Australia was
set up to advise on the practical aspects of monitoring
ART renal function in the absence of hard evidence.
This took the form of a number of meetings where the
evidence for nephrotoxity was sought and presented by
various members of the panel (all of whom appear as
authors of this paper) and based upon this a consensus
monitoring algorithm was synthesised.
Tenofovir
The prodrug tenofovir disproxil fumarate (TDF) is given
because tenofovir (TFV) has poor oral bioavailability, but
once absorbed TDF is rapidly hydrolysed to TFV. TFV is
a potent nucleotide analogue reverse transcriptase inhibi-
tor with activity against HIV and hepatitis B virus (HBV).
Circulating TFV is taken up by endocytosis in most cells
(except in the renal tubule where specific transporters are
present) and rapidly phosphorylated further forming a
nucleoside analogue that causes chain termination in
HIV reverse transcriptase or HBV DNA polymerase [19].
The volume of distribution is within total body water, and
TFV is mainly renally excreted with little hepatic metabol-
ism. Of note TFV excretion exceeds glomerular filtration
rate (GFR), so tubular secretion is thought to contribute
20–30% to its elimination.
A new formulation of TFV, tenofovir alafenamide (TAF,
formerly GS-7340), is currently being evaluated in Phase
III clinical trials. TAF is more stable in plasma and is pre-
dominantly hydrolysed to TFV intracellularly by cathepsin
A in lymphocytes and macrophages. This results in high
intracellular levels of the active phosphorylated tenofovir
but reduced plasma levels of TFV. A recent phase II study
showed significantly smaller changes in estimated creatin-
ine clearance, renal tubular proteinuria than TDF [20].
Evidence for renal effects
In the early randomised controlled trials of TDF vs. thymi-
dine analogues in HIV [21-23] and subsequent follow-upstudies there were small but statistically insignificant
differences in renal function but no signals suggesting
nephrotoxicity [12,24-26]. However these studies involved
relative healthy subjects and relied on measured changes
in the serum creatinine (SCr). A series of case reports,
predominantly of Fanconi syndrome started appearing in
2002 [27] and, propelled a re-examination of the renal
safety data. The Viread Expanded Access Program [12]
involving more than 10,000 people reported serious ad-
verse renal events in 1.5 individuals per 1000 patient-
years. Various cohort studies have subsequently reported
associations between TDF exposure and small but statisti-
cally significant declines in estimated glomerular filtration
rate (eGFR) over time. A recently published large cohort
study of 22,603 HIV-infected persons [28] with a median
follow up of 4.5 years (after 1January 2004) found that
cumulative TDF, ritonavir-boosted atazanavir and
ritonavir-boosted lopinavir use were all independent
predictors of chronic renal impairment (confirmed eGFR
of ≤70 mL/min) however, cumulative TDF use was not a
significant predictor of CKD (eGFR of ≤60 mL/min). In a
follow up publication expanded to over 35,000 patients
with 200,119 person years of follow up 0.4% developed ad-
vanced renal failure (eGFR < 30) and 0.06% developed
end-stage renal failure [29]. Further, the data showed that
whilst TDF was discontinued as GFR fell, current or previ-
ous drug use did not predict these outcomes and only
traditional risk factors and CD4 count were associated
with increased risk. In a meta-analysis of 11 studies
[13] there was an estimated mean reduction in eGFR of
3.92 mL/min among the TDF recipients compared with
control subjects. Although this reduction was statistically
significant, the magnitude was modest in clinical terms.
This analysis also found no evidence that TDF use led to
increased risk of CKD, severe proteinuria, hypophospha-
taemia or fractures. However, a large retrospective US co-
hort of 10,841 HIV-infected subjects [14] reported a small
but significant increase in the relative risk of CKD (HR
1.44, 95% CI 1.3-1.6) and proteinuria (HR 1.30, 1.22-1.37)
with TDF exposure, that was greatest in those with more
than 3 years of exposure suggesting that monitoring of
renal function should continue long-term.
Labarga et al. [30] reported that over time, subclinical
proximal tubular dysfunction can develop, involving rela-
tively low level proteinuria and phosphaturia, but in the
absence of an impaired GFR. This occurred in up to 22%
of closely monitored HIV patients treated with TDF. It
was interesting to note that tubular dysfunction was also
seen in 12% of ART-naïve patients. Although this dys-
function did not appear to have clinical sequelae it is
nevertheless of concern not only for renal function but
also potentially for future bone health.
TDF is associated with Fanconi syndrome (protein-
uria, hypokalaemia, hypophosphataemia, phosphaturia,
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(AKI). Based on the available data, the frequency of
Fanconi syndrome/AKI associated with TDF in HIV-treat
patients is < 1% [12,13]. In the expanded access program,
a serious adverse renal event of any type was observed in
0.5% of patients, with failure (acute and chronic) reported
in 0.3% and Fanconi syndrome in <0.1% [12]. In the meta-
analysis the estimated increased risk of AKI was 0.7% [13].
Importantly, in many cases the renal dysfunction is
fully reversible, and if detected early more likely to do so
whilst if ignored could lead to dialysis requirements. Jose
et al. reports that if detected TDF toxicity appears revers-
ible in around half of cases within a year but recovery can
be prolonged and may continue for over 5 years [31]. In
this study between ~7-28% of patients did not fully re-
cover, depending on the definition of full recovery. This
study also showed that those with the largest change in
GFR at discontinuation had a higher baseline GFR, and
the duration of TDF treatment were the best determinants
of incomplete recovery, making it important that initial
and subsequent GFRs are recorded and compared [31].
No studies have fully addressed the concept of a TDF dose
reduction in order to improve renal function and we
do not endorse this strategy at present. Patients who
have evidence of progressive nephrotoxicity, which only
partially reverses with cessation of TDF, probably should
not go back on this drug.
A South-African study has reported the association be-
tween nephrotoxicity (any decline in renal function from
baseline) or death and baseline renal function [32]. They
reported TDF nephrotoxicity in 2.4%, and those at highest
risk of death were those with pre-existing renal dysfunc-
tion. Those who were switched from other regimens onto
a TDF-containing regimen were also at highest risk of
nephrotoxicity.
Pathophysiology of renal injury
In the proximal tubules, high intracellular concentrations
of TFV are thought to disrupt mitochondrial function af-
fecting their number, size, shape and internal morphology
[33]. TFV has a low inhibitory effect on mitochondrial
DNA (mtDNA) polymerase-γ, which is important for
mitochondrial replication. Depleted levels of mtDNA
can lead to defects in electron transport chain function
and oxidative phosphorylation causing a reduction in
ATP generation and impaired energy production that
may result in reduced resorptive capacity for ions and
other molecules (e.g. phosphate and glucose), especially
in the highly metabolically demanding and relatively
hypoxic environment of the proximal tubule [34].
Although TFV is only a weak inhibitor of mtDNA γ-
polymerase [35] the presence of a number of factors
may combine to increase the risk of TFV tubulopathy in
some HIV-infected individuals. Of note however, is thefact that the HIV virus itself causes mtDNA depletion,
and this could be relevant when considering hypopho-
sphataemia, including patients not on ART. TFV enters
proximal tubular cells across the basolateral membrane
via organic anion transporters (OAT1 and OAT3), and
exits the tubule across the apical membrane via multidrug
resistance protein transporters (MRP4 and possibly MRP2)
coded for by the ABC cassette genes [36] (Figure 1).
Co-administration of antiretroviral drugs that are also
processed by these transporters (potentially affecting
efflux) including ritonavir (MRP2) and didanosine (OAT1),
have been implicated in many of the reports of TDF-related
Fanconi syndrome. In a review of 164 cases received by
the FDA Adverse Reporting System, 74% of patients were
also taking a ritonavir-boosted protease inhibitor and 43%
were taking didanosine (now rarely used) [37].
Declining glomerular filtration due to age or co-existing
CKD can result in a shift towards increased tubular secre-
tion of TFV and other factors such as low body weight,
may increase plasma TFV levels, have also be shown to be
risk factors for TDF-related tubulopathy. Finally poly-
morphisms in genes associated with tubular transporter
proteins may affect the flux of TFV into and out of
proximal tubular and may help to explain why tubulo-
pathy occurs in only some individuals, but this data is
some way from being clinically useful [38-41].
Cobicistat
The inclusion of cobicistat in the recently introduced
co-formulated tablet Stribild® (cobicistat + elvitegravir +
emtricitabine + TDF), adds an extra dimension to the
renal monitoring in patients receiving this TDF-based
single tablet regimen. Cobicistat, which has no intrinsic
anti-HIV activity, is a potent cytochrome P450 3A (CYP3A)
inhibitor and is used as a pharmacoenhancer to boost and
maintain the therapeutic plasma concentration of the
HIV integrase inhibitor elvitegravir over the 24-hour
dosing interval. Cobicistat also reduces proximal tubular
secretion of creatinine by inhibiting cation transporters
(particularly MATE 1) in a manner similar to cimetidine
or trimethoprim. This may have implications on other
drug metabolism. It does however have the potential to
interact with other drugs that are metabolised by CYP3A
(e.g. azol anti-fungals, warfarin, salmeterol and some
statins) or those excreted by MATE1 (metformin in
particular) [42]. Cobicistat leads to a modest, rapid (days)
and reversible, increase in SCr, and therefore an apparent
reduction in eGFR, but not GFR measured by iohexol
clearance [43]. In the phase III registration studies
(GS102/103) these studies involved >1400 treatment naïve
patients followed to 144 weeks, the increase in SCr
concentration (mean ~12.4 ± 11.5 μmol/L) stabilised after
2–4 weeks76. This baseline change needs to be considered
when monitoring renal function in patients receiving
Figure 1 Ion transporters involved in proximal tubular cell handling of creatinine and antiviral drugs.
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immediate increase of SCr from baseline <35 μmol/L
(which is taken from the mean +2 SD of the Stribild
trials) be considered a range that would capture ~98%
of the expected increases in patients with normal renal
function and does not require additional investigation
providing it is stable at this level.Rilpivirine
Rilpivirine is a non-nucleoside reverse transcription in-
hibitor, which is minimally excreted by the kidney. A small
increase in serum creatinine (~8.8 μmol/L =0.1 mg/dL
in the TDF backbone regimen) has been noted in
studies [44,45] and it too has been shown to inhibit
a number of transporters including the organic cat-
ion transporter protein 2 (OCT2) and p-glycoprotein
(pg-p) [46].
The former inhibits tubular secretion of creatinine,
as cystatin C measurements of renal function are
unaffected. However cystatin C based equations appear
to be less accurate in patients with HIV taking ART
[47,48].Dolutegravir
Dolutegravir is an HIV integrase inhibitor, again largely
not excreted by the kidney and again inhibiting OCT2
[49] resulting in a small rise in creatinine (by ~7.6 μmol/L
in normal individuals [50]) without affecting GFR by
iohexol clearance [51].Tenofovir in HBV
Compared to the situation in HIV, the incidence of
tubulopathy with TDF when used in chronic hepatitis B
(HBV) appears to be lower, although two cases of revers-
ible Fanconi Syndrome have recently been reported [52].
This may simply reflect ascertainment or reporting bias
as experience of TDF use in HBV therapy is relatively
small compared to use in HIV. However there may be
key differences in the HBV-infected compared to the
HIV-infected population, for example HIV-infected pa-
tients are more likely to be taking concomitant
nephrotoxic drugs and, unlike HIV, the HBV does not
appear itself to affect mitochondrial function [53]. In
addition HBV is known to be associated with glomer-
ulonephritis with [54], or without [55] evidence of viral
replication which often responds to viral suppression
and that may in fact improve renal function.
Reporting of renal function (eGFR, SCr and serum
phosphate, but not proteinuria) in both the long-term
follow-up of the TDF HBV clinical trials in abstract form
(7 years to date) and at least five prospectively-followed
cohorts of patients with chronic hepatitis B (both
treatment-naïve and -experienced) have revealed gener-
ally fewer changes in creatinine despite the latter cohort
having a number of risk factors for renal disease.
The European Association for the Study of the Liver
(EASL) 2012 management guidelines recommend only
that “Renal function should be monitored during antiviral
treatment” [56]. Similarly the Asian Pacific consensus rec-
ommends “close observation on proximal tubular injury
Holt et al. AIDS Research and Therapy 2014, 11:35 Page 5 of 10
http://www.aidsrestherapy.com/content/11/1/35and bone toxicity must be maintained” [57]. In contrast
the Gastroenterology Society Australia [58] and American
Association for the Study of the Liver (AASLD) [59]
suggests checking the serum creatinine every 12 weeks
for patients on adefovir or tenofovir. Whilst awaiting
further work in this area and since viral parameters are
usually being measured 3–6 monthly, we encourage the
addition of a serum creatinine estimation at these time
points. However we feel it would be reasonable to check
the same parameters (eGFR, plasma phosphate, uPCR
and for glycosuria) at least yearly in patients on TDF.
Renal monitoring
In 2005, the Infectious Diseases Society of America
recommended that all patients recently diagnosed with
HIV infection should be screened for kidney abnormal-
ities including SCr for calculation of eGFR and urinalysis
dipstick for proteinuria, with annual screening for at-risk
patients [60]. The more recent US DHHS suggest basic
chemistry 3–6 monthly (Serum Na, K, HCO3, Cl, BUN,
creatinine) and glucose (preferably fasting), with a sugges-
tion that phosphorus levels should be taken in patients
on TDF [18]. The more recent European AIDS Clinical
Society guidelines recommend 3–12 monthly monitor-
ing of eGFR and annual dipstick analysis for proteinuria
with more frequent monitoring in high-risk groups for
CKD. The Australasian Society for HIV Medicine com-
mentary on the US DHHS guidelines recommends urin-
alysis (6 monthly) and electrolyte monitoring (including
serum phosphate) in patients prescribed TDF in addition
to routine renal monitoring of HIV-infected patients;
again with more frequent monitoring in those with an in-
creased risk of renal insufficiency.
TDF HIV renal management algorithm
Given the central role of TDF-based therapy and the po-
tential for tubulopathy associated with TDF, we suggest
active monitoring to maximise the drug’s continued
utility. These suggestions are outlined in the algorithm
in Figure 2. It is important to note that this algorithm
complements the Kidney Health Check7 (SCr (and thus
also eGFR), albumin/creatinine ratio (uACR) and blood
pressure) recommended every 1–2 years for patients
with diabetes, hypertension, obesity (BMI ≥ 30), estab-
lished CVD, smokers, those with a family history of CKD,
and those of Aboriginal or Torres Strait Islander origin.
This is in order to detect subclinical renal disease and to
identify those patients with a higher cardiovascular risk or
the small cohort who may go on to develop declining
renal function. We suggest such monitoring is also appro-
priate for those who are on a non –TDF regimen. The key
differences for patient on TDF based regimens is that
urine total protein-to-creatinine ratio (uPCR) should be
used, rather than uACR, and the additional measurementof a serum phosphate level. The measurement of blood
pressure is important for detecting cardiovascular and
renal risk generally. Patients who may be at high risk of
developing renal dysfunction include those;
 With co-infection with viral hepatitis
 Concomitant nephrotoxic medication (especially
non-steroidal anti-inflammatory drugs (NSAID))
 With diabetes
 Who are Aboriginals, Torres Straight islanders or
black Africans
 Who have a family history of renal disease
 With hypertension
 With pre-existing cardiovascular or renal disease
 With uncontrolled or untreated HIV
 With a low BMI (<18.5)
GFR estimates
In Australia, the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula has largely replaced
the Modification of Diet in Renal Disease (MDRD) equa-
tion for calculating eGFR [61]; CKD-EPI helps prevent
underestimates of GFR particularly at the higher ranges
of GFR [62]. Both equations have shown a reasonable
degree of agreement in stratifying baseline eGFR in HIV
positive population, although a recent publication sug-
gests that CKD-EPI best approximates measured GFR
in this group [63]. The differences between CKD-EPI
eGFR and Cockcroft-Gault (CG) formula estimations of
creatinine clearance are very modest (3.2 (IQR −0.6 to
7.4 mL/Min/1.73 m2)) and typically have equal preci-
sion. Although recommendations for dose adjustment
are typically quoted as creatinine clearance (CrCl), we
suggest using the CKD-EPI formula and in this context,
and this can be used interchangeably with CrCl for TDF
dose modification [64]. Cystatin C based equations cannot
be recommended for renal monitoring in HIV positive in-
dividuals because its generation is affected by HIV itself
and a number of antivirals [47,48,65].
Abnormal baseline tests
If patients have abnormal test results at baseline, treat-
able reasons for kidney disease should be excluded and
the patient’s risk of CVD assessed and managed with
lifestyle modification and medication, as appropriate, to
control hypertension (ACE inhibitor or angiotensin II
receptor blockers as first line therapy), dyslipidaemia
and hyperglycaemia. Nephrotoxic medications should
be avoided and medication doses adjusted for renal
function. The prescriber should consider carefully the
appropriateness of commencing TDF, which may require
a dosing interval adjustment (as detailed in the product
information)75 in all patients with CrCl/eGFR < 50 (see
Table 1). Stribild should not be initiated in patients with
Table 1 TDF dose reduction strategies
Creatinine clearance Dosing interval for TDF 300 mg
(or eGFR – CKD-EPI)
>50 Every 24 hrs
30-49 Every 48 hrs*
10-29 Every 72–96 hrs*
Haemodialysis After dialysis every 7 days or
after ~12 hrs of dialysis*
*Consider whether TDF is the appropriate antiviral.
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CrCl falls to < 50, it should be discontinued because the
required dose interval adjustments are not possible using
this fixed dose combination tablet.Proteinuria
A reduction in tubular ATP production may also allow
enhanced urinary loss of low molecular weight proteins
(e.g. ß2-microglobulin and retinol binding protein) which
are usually freely filtered but reabsorbed by active pro-
cesses involving megalin and cubilin. In contrast to
glomerular disease, where large proteins such as albumin,
are lost in the urine, the glomerular filtration barrier in
TDF-associated renal injury is often relatively intact. This
means that checking the urine for albumin alone (as
recommended in the Kidney Health Australia (KHA)
guidelines for detection of renal disease) may miss pro-
teinuria due to tubular dysfunction. We recommend the
use of uPCR since this will detect all urinary protein,
not simply albumin. Thus glomerular disease (which
may cause predominantly albuminuria) and/or tubular
proteinuria (which may cause low molecular weight
proteinuria) will both be detected if present [66]. A ratio
of uACR to uPCR <0.4 has been suggested as a useful tool
to distinguish between the two in HIV positive cohorts
[67] and has been found to be helpful in determining the
aetiology of proteinuria [68]. Dipstick urinalysis for pro-
tein is mainly sensitive to albumin, and especially in dilute
urine may miss other (tubular) proteinuria [69].Glycosuria
Any method for detecting urinary glucose is valid and a
dipstick is a good test. If the patient is diabetic then the
test should be performed with a blood glucose estimation
to ensure normoglycaemia at the time of the test. Glyco-
suria is not normal under any circumstance (apart from
pregnancy and the rare glucose transporter defects, or
with patients on the new glut 2 inhibitors) [70]. Dipstick
urinalysis is sensitive to glycosuria but can be negative in
the face of high vitamin C intake [69]. New glycosuria
with normal serum glucose should warrant urgent repeat
and if confirmed discontinuation of TDF.Serum phosphate
Serum phosphate levels below the reference range can
occur in diverse range of conditions including untreated
HIV infection. Thus, the presence of hypophosphataemia
should be confirmed on a fasting specimen and other
potential causes investigated.
Moderate hypophosphataemia (0.65–0.8 mmol/L) is
often transient, benign and of unknown significance.
Follow up isolated hypophosphataemia would be onerous,
expensive, and largely unhelpful, and simply warrants
monitoring at the next routine visit with a morning fasting
sample. However, if the serum phosphate falls below
0.65 mmol/L, further investigation [71] may be appropri-
ate particularly looking for features of Fanconi syndrome
triad [72] (hypophosphataemia, glycosuria with normal
serum glucose, mild proteinuria). Other biochemical
features may include hypokalaemia, hypouricaemia, low
serum bicarbonate, low serum urate. Clinical features may
be polyuria and polydipsia, lassitude and bone pains.
Conditions associated with hypophosphataemia (adapted
from [68]) include;
 alcohol excess
 concomitant drugs (e.g. antacids and phosphate
binders, diuretics, bisphosphonates, corticosteroids)
 the Fanconi syndrome either inherited or acquired
(e.g. cisplatinum, ifosphamide, antivirals)
 rare syndromes associated with FGF23 excess
inherited (e.g. X-linked hypophosphataemia) or
acquired (e.g. tumour induced osteomalacia), iron
infusion
 a glucose or insulin load
 those with hepatic impairment
 primary hyperparathyroidism
 malabsorption syndromes
 a respiratory alkalosis (hyperventilation)
 untreated HIV
Reasons for nephrology referral
If the Fanconi syndrome is confirmed then TDF should
be stopped and the patient changed to a non-TDF con-
taining ARV regimen, and renal function and proteinuria
followed carefully with monthly testing until these features
have resolved. If no improvements in these abnormalities
are apparent within a month then a nephrological review
is strongly recommended. Other situations when referral
to a nephrologist with an interest in HIV or specialist HIV
physician include:
 eGFR < 30 mL/min
 Ongoing significant proteinuria (uPCR >50 mg/mmol)
 A consistent decline in eGFR from baseline
< 60 mL/min (i.e. decline > 5 mL/min over a
6-month period, confirmed ≥ 3 separate readings)
Figure 2 Schematic of suggested renal monitoring when starting drugs which are potentially nephrotoxic.
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 CKD and difficult to control hypertension
despite ≥ 3 antihypertensive agents
 Microscopic or macroscopic haematuria alone
should also be referred for urine cytology, imaging
and possibly cystoscopy.
If renal dysfunction is not related to a full Fanconi
syndrome, but thought to be related to TDF, then a
prompt switch away from TDF-based antivirals is almost
always the best choice. However, it is our observation is
that this switch is sometimes made where the evidence
implicating TDF for the renal decline is scarce or
non-existent, and often without considering alterna-
tive diagnoses. The implications are that TDF is then
unavailable for future use in that individual, which
significantly narrows the antiviral regimen choice. Thus
the decision to stop a regimen, which is usually success-
fully supressing virus, is not a trivial one and should be
made by weighing the evidence implicating a particular
drug in the renal decline.
Frequency of follow up
Most international guidelines suggest at least yearly
follow up of renal function, which we consider the
minimum frequency for good care of patients with
HIV-infection. Some authors advocate testing 3 monthly
in the first year and yearly thereafter [73], as those who
are well with completely normal tests in the first12 months appear to be at lower risk of nephrotoxicity.
The data for TDF suggest that the risk of nephrotoxicity
may increase over time in at-risk patients [14]. We
therefore suggest more frequent (3–6 monthly) review
of patients with identified renal disease (e.g. CKD, mild
proteinuria or hypophosphatemia but without glycosuria)
particularly when a dose adjustment may be needed
(Figure 2). Any patient with the Fanconi syndrome
should be re-tested monthly until there are improve-
ments in biochemistry and then every 3 months until
back to baseline function and referred for specialist
review by an HIV physician or a nephrologist with an
interest in HIV. We feel it would be sensible for high
risk-patients on TDF for HBV mono-infection infection
to have similar renal investigations at least yearly. Patients
who are not on nephrotoxic antiviral agents may still be at
higher risk of developing renal dysfunction associated with
non drug related issues and ageing. Thus a yearly Kidney
Health Check [7] would appear be appropriate in these
patients.
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